Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

NCT03295227 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Stage III Thymoma AJCC v8
Stage IIIA Thymoma AJCC v8
Stage IIIB Thymoma AJCC v8
Stage IV Thymoma AJCC v8
Stage IVA Thymoma AJCC v8
Stage IVB Thymoma AJCC v8
Unresectable Thymic Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)